Dr. Agarwal’s merger decoded: – When two pairs of spectacles become one lens

Opening Hook

Healthcare M&A is suddenly hotter than the latest Apple Vision Pro. And Dr. Agarwal’s just sharpened the focus: merger of Dr. Agarwal’s Eye Hospital Ltd (AEHL) into Dr. Agarwal’s Health Care Ltd (AHCL), India’s largest eye-care chain. Together, they clocked ₹2,113 crore revenue in FY25 (Investor Presentation, Aug 2025) with EBITDA margins in the 29–31% zone—rare clarity in healthcare. Why does it matter? Because eye care is a fragmented ₹20,000+ crore industry, and this deal could turn Dr. Agarwal’s into the undisputed Apollo of ophthalmology. Stick around—things get sharper two scrolls down.

At a Glance

• AHCL revenue ₹1,711 cr, PAT ₹110 cr – margins that don’t need glasses.
• AEHL revenue ₹402 cr, PAT ₹55 cr – Tamil Nadu titan ready for rollout.
• Share swap – 23 AHCL shares for 2 AEHL shares (~15% premium).
• Preferential issue – ₹70 cr to AHCL for capex pre-merger.
• Timeline – Q2 FY27 completion (NCLT, SEBI approvals pending).
• Network – 293 facilities across India & Africa; 3 lakh+ surgeries a year.

Management’s Key Commentary

“The merger will simplify the group structure.”
Translation: One entity, fewer compliance headaches, less CA overtime.

“It will be EPS accretive from year one.”
Translation: Please clap, we actually checked the math this time.

“AHCL is India’s largest eye-care services chain with 230 facilities.”
Translation: Our posters are everywhere from Madurai to Mozambique.

“AEHL facilities grew 2.4x since FY22.”
Translation: Tamil Nadu residents are running out of excuses for cataracts.

“The unified platform will unlock shareholder value.”
Translation: Bigger balance sheet = easier fundraising pitch deck.

“Net debt position: negative ₹278 cr.”
Translation: We’re sitting on cash, not sweating EMIs.

Numbers Decoded